Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tivozanib + Enzalutamide in Adv Prostate Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Massachusetts General Hospital
Sponsor:
Collaborator:
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Dror Michaelson, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01885949
First received: June 19, 2013
Last updated: September 17, 2014
Last verified: September 2014
  Purpose

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational combination of drugs to learn whether they work in treating a specific cancer. "Investigational" means that the combination of drugs is still being studied and that research doctors are trying to find out more about it, such as the safest dose to use and the side effects they may cause. It also means that the FDA has not yet approved the combination.

The two drugs being tested in this study are tivozanib and enzalutamide. Enzalutamide has been approved by the FDA for treatment of prostate cancer. On the other hand, tivozanib is still investigational, and has not been tested in a combination with enzalutamide before.

Enzalutamide is an androgen receptor antagonist (it blocks the activity of the male sex hormones). Prostate cancers are initially dependent on the male hormone testosterone for growth. Hormonal therapies that lower testosterone or block the ability of testosterone to act at the level of the prostate cancer are currently among the most effective treatments for prostate cancers taht have spread to other body organs (metastasized). The effectiveness of hormonal treatments, however, is not permanent, and over time many prostate cancers progress in spite of these treatments. Enzalutamide is a drug that has been proven to help delay the progression of advanced prostate cancer on average for about 8 months.

Tivozanib is an anti-angiogenesis medicine that fights different types of cancer by blocking the blood supply to the tumor, so that the tumor does not receive the nutrients it needs to grow. The main goal of this study is to determine whether the combination of tivozanib and enzalutamide is more effective in delaying the progression of disease than when enzalutamide is given alone. This study will also determine whether treatment with the combination of the tivozanib and enzalutamide will have more side effects then treatment with enzalutamide alone.


Condition Intervention Phase
Prostate Cancer
Drug: Tivozanib
Drug: Enzalutamide
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 2 Combination Trial of Tivozanib and Enzalutamide in Men With Advanced Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Progression Free Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    The primary objective of this study will be to demonstrate an improvement in progression free survival in men with metastatic castration resistant prostate cancer (mCRPC) treated with tivozanib and enzalutamide.


Secondary Outcome Measures:
  • Safety and Tolerability [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Safety and tolerability of tivozanib and enzalutamide will be assessed. The number of patients having grades 1-4 adverse events by NCI CTC version 4.0 will be recorded.

  • Overall Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To estimate overall survival in patients treated with tivozanib and enzalutamide

  • PSA Response rate [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To evaluate PSA response rate

  • Time to PSA Progression [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    The time to PSA progression (in months) will be evaluated in patients treated with enzalutamide and tivozanib


Estimated Enrollment: 42
Study Start Date: June 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Experimental Treatment Arm
Tivozanib, taken daily for 21 days followed by a 7 day break Enzalutamide taken daily for 28 days
Drug: Tivozanib
Oral
Other Name: AV-951
Drug: Enzalutamide
oral
Other Name: MDV-3100

Detailed Description:

Patients will be treated in treatment cycles of 28 days (4 weeks), during which time they will take tivozanib once a day for 21 days (3 weeks) followed by a one week break from treatment. The other medication, enzalutamide, will be taken every day throughout each cycle.

Patients will be given a Study Drug Administration Diary to keep a brief record of medication administration, and to record any side effects or symptoms.

Patients will be seen in the clinic at the beginning of each cycle (every 4 weeks). During each visit they will have the following procedures: medical history, vital sign measurements, complete physical examination, performance status, routine blood tests, urine sample, prostate specific antigen (PSA) test, assessment of tumor, review of study drug administration diary, and review of current medications.

About four weeks after stopping the study drug patients will be asked to return to the research clinic for a final study visit. The following procedures will be done: medical history, vital sign measurements, brief physical examination, electrocardiogram, review of other medications used since the last visit, routine blood tests, urine sample and a review of any changes in health.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adenocarcinoma of the prostate that is metastatic or unresectable and for which standard curative options do not exist
  • Radiographic evidence of metastatic prostate cancer
  • Progressive disease despite ongoing androgen deprivation therapy (ADT), defined as castration resistant prostate cancer (CRPC)
  • Other than ongoing prior treatment with other hormonal agents such as antiandrogens or ketoconazole must have been stopped at least two weeks prior to enrollment
  • Have received prior docetaxel-based chemotherapy for prostate cancer within the past 12 months. Such chemotherapy must have been stopped at least 3 weeks prior to the first dosing in this study
  • Life expectancy of at least 12 weeks
  • Must agree to use adequate contraception prior to study entry and for the duration of study participation

Exclusion Criteria:

  • Prior treatment with enzalutamide, TOK-001, or ARN-509
  • Participants who have received more than two prior chemotherapy regimens for metastatic CRPC
  • Receiving any other investigational anticancer agents
  • Known brain metastases
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to tivozanib or enzalutamide
  • Radiotherapy or minor surgical procedure within 2 weeks, or major surgical procedure within 4 weeks prior to administration of first dose of study drug; inadequate recovery from prior surgical procedure
  • History of seizure of condition that may predispose to seizure
  • Significant cardiovascular disease
  • Non-healing wound, bone fracture or skin ulcer
  • Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis or other gastrointestinal condition with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to administration of first dose of study drug
  • Serious/active infection or infection requiring parenteral antibiotics
  • Significant thromboembolic or vascular disorders within 6 months prior to administration of first dose of study drug
  • Currently active second primary malignancy, including hematologic malignancies, except for non-melanoma skin cancers, in situ cervical cancer, and ductal or lobular carcinoma in situ of the breast
  • History of genetic or acquired immune suppression disease such as HIV; subjects on immune suppressive therapy for organ transplant
  • Inability to swallow capsules, malabsorption syndrome or gastrointestinal disease that severly affects the absorption of study drugs, major resection of the stomach or small bowel, or gastric bypass procedure
  • Significant bleeding disorders within 6 months prior to administration of first dose of study drug
  • Psychiatric disorder or altered mental status precluding informed consent or protocol-related testing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01885949

Contacts
Contact: M. Dror Michaelson, MD, PhD 6177261594 dmichaelson1@partners.org

Locations
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Carol Gurski, RN    617-643-1770    cgurski@partners.org   
Principal Investigator: M. Dror Michaelson, MD, PhD         
Sponsors and Collaborators
Massachusetts General Hospital
National Comprehensive Cancer Network
Investigators
Principal Investigator: M. Dror Michaelson, MD, PhD Massachusetts General Hospital
  More Information

No publications provided

Responsible Party: Dror Michaelson, MD, Principal Investigator, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01885949     History of Changes
Other Study ID Numbers: 13-073
Study First Received: June 19, 2013
Last Updated: September 17, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Massachusetts General Hospital:
Metastatic

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on November 23, 2014